All In Biotech

Free tool

FAERS Monitor: Emrelis

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761384 or its brand name (Emrelis, Telisotuzumab Vedotin-Tllv). Reports on generic versions are filed under their own applications.

Reports

78

Serious

34

44% of reports

Hospitalization

18

Death reported

9

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use8
  • neuropathy peripheral7
  • keratitis6
  • disease progression5
  • interstitial lung disease4
  • pneumonia4
  • vision blurred4
  • death3
  • pneumonitis3
  • agranulocytosis2
  • fatigue2
  • ocular toxicity2
  • product storage error2
  • product temperature excursion issue2
  • pulmonary embolism2

Reports by year received

View as table
YearReports
20181
20231
20243
202523
202650

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,081 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
keratitisSignal6533.3247.02,673
ocular toxicity2489.9124.6547
product temperature excursion issue2105.026.7115
pneumonitisSignal329.79.857
agranulocytosis229.07.430
interstitial lung diseaseSignal422.38.662
neuropathy peripheralSignal719.89.8108
disease progressionSignal511.44.938
vision blurredSignal47.93.018
product storage error26.21.64
pulmonary embolism25.71.44
pneumoniaSignal43.31.34
off label useSignal82.51.36
death30.90.30
fatigue20.70.20

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.